RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 Cardiovascular Safety of Linagliptin Demonstrated in Pooled Analysis
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 17
SP 15
OP 22
DO 10.1177/155989771317012
UL http://mdc.sagepub.com/content/13/17/15.abstract
AB The cardiovascular (CV) safety of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus has been supported by a pooled comprehensive analysis of prospectively adjudicated CV events in Phase 3 studies. CV benefit with linagliptin is being tested prospectively in the CAROLINA study [NCT01243424] against glimepiride and in the CARMELINA study [NCT01897532] against placebo. The pooled analysis included 9459 patients from 19 United States or multinational, multicenter, double-blind, parallel-group studies.